Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

Templeton, A. J., McNamara, M. G., Šeruga, B., Vera-Badillo, F., Aneja, P., Ocaña, A., Leibowitz‐Amit, R., Sonpavde, G., Knox, J. J., Tran, B., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju124 · Cited by 3,304

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

Cristescu, R., Mogg, R., Ayers, M., Albright, A., Murphy, E., Yearley, J., Sher, X., Liu, X. Q., Lu, H., Nebozhyn, M., et al. (2018) · Science · doi:10.1126/science.aar3593 · Cited by 2,301

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119

Effectiveness of meaning‐centered interventions on existential distress and mental health outcomes in cancer survivors and their family caregivers: A systematic review and meta‐analysis of randomized controlled trials

Wang, Z., Xu, D., Yu, S., Liu, Y., Han, Y., Zhao, W., & Zhang, W. (2024) · Worldviews on Evidence-Based Nursing · doi:10.1111/wvn.12752 · Cited by 27

Systemic immune-inflammatory index predict short-term outcome in recurrent/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor

Chen, Q., Zhai, B., Li, J., Wang, H. Z., Liu, Z., Shi, R., Wu, H., Xu, Y., & Ji, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-82976-6 · Cited by 23

Platelet-white cell ratio is more strongly associated with mortality than other common risk ratios derived from complete blood counts

Foy, B. H., Carlson, J., Aguirre, A. D., & Higgins, J. M. (2025) · Nature Communications · doi:10.1038/s41467-025-56251-9 · Cited by 27

Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis

Liu, T., Li, W., Zhang, Z., Jiang, T., Fei, Y., Huang, J., & Xie, Q. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02106-8 · Cited by 23

Prognostic Value of Systemic Immune-Inflammation Index (SII) in Patients with Glioblastoma: A Comprehensive Study Based on Meta-Analysis and Retrospective Single-Center Analysis

Yang, C., Hu, B.-W., Tang, F. R., Zhang, Q. H., Quan, W., Wang, J., Wang, X., Li, Y., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247514 · Cited by 24

A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors

Kang, D., Liu, S.-P., Yuan, X., Liu, S.-X., Zhang, Z.-R., He, Z.-M., Yin, X.-D., & Mao, H.-Y. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05504-5 · Cited by 20

Serum albumin and derived neutrophil-to-lymphocyte ratio are potential predictive biomarkers for immune checkpoint inhibitors in small cell lung cancer

Kuang, Z., Miao, J., & Zhang, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1327449 · Cited by 23

Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?

Goff, P. H., Bhakuni, R., Pulliam, T. H., Lee, J. H., Hall, E. T., & Nghiem, P. (2021) · Cancers · doi:10.3390/cancers13143415 · Cited by 23

Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab

Thor, M., Shepherd, A. F., Preeshagul, I. R., Offin, M. D., Gelblum, D. Y., Wu, A. J.-C., Apte, A., Simone, C. B., Hellmann, M. D., Rimner, A., et al. (2021) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2021.12.016 · Cited by 22

Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review

Huang, Y., Cho, H. J., Stranger, B. E., & Huang, R. S. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-1013 · Cited by 23

Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?

Lee, C., Chan, S., & Chon, H. (2022) · Cancers · doi:10.3390/cancers14133213 · Cited by 19

Circulating neutrophils activated by cancer cells and M2 macrophages promote gastric cancer progression during PD-1 antibody-based immunotherapy

Zhou, C., Guo, L., Cai, Q., Xi, W., Yuan, F., Zhang, H., Yan, C., Huang, L., Zhu, Z., & Zhang, J. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1081762 · Cited by 21

Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies

Jang, A., Lanka, S. M., Jaeger, E., Lieberman, A., Huang, M., Sartor, O. A., Mendiratta, P., Brown, J. R., Garcia, J. A., Farmer, T. E., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00131 · Cited by 21

Prognostic Value of Blood-Based Inflammatory Markers in Cancer Patients Receiving Immune Checkpoint Inhibitors

Mıdık, M. M., Günenç, D., Acar, P. F., & Karaca, B. S. (2024) · Cancers · doi:10.3390/cancers17010037 · Cited by 20

Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology

Abboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., Al-Shamsi, H. O., Javle, M. M., Saharia, A., Connor, A. A., Kodali, S., et al. (2023) · Cancers · doi:10.3390/cancers15051433 · Cited by 21

The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy

Prelaj, A., Ganzinelli, M., Trovò, F., Roisman, L. C., Pedrocchi, A., Kosta, S., Restelli, M., Ambrosini, E., Broggini, M., Pravettoni, G., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.02.005 · Cited by 20

Comparison of single-cell RNA-seq methods to enable transcriptome profiling of neutrophils in clinical samples

Hatje, K., Schneider, K., Danilin, S., Köchl, F., Giroud, N., Juglair, L., Marbach, D., Knuckles, P., Bergauer, T., Metruccio, M. M. E., et al. (2025) · Cell Reports Methods · doi:10.1016/j.crmeth.2025.101173 · Cited by 19

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade

Sarfaty, M., Golkaram, M., Funt, S. A., Al‐Ahmadie, H. A., Kaplan, S., Song, F., Regazzi, A. M., Makarov, V., Kuo, F., Ostrovnaya, I., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02144 · Cited by 19

Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer

Licata, L., Mariani, M., Rossari, F., Viale, G., Notini, G., Naldini, M. M., Bosi, C., Piras, M., Dugo, M., & Bianchini, G. (2023) · The Breast · doi:10.1016/j.breast.2023.03.014 · Cited by 19

Tertiary lymphoid structure and neutrophil–lymphocyte ratio coordinately predict outcome of pembrolizumab

Komura, K., Tokushige, S., Ishida, M., Hirosuna, K., Yamazaki, S., Nishimura, K., Ajiro, M., Ohno, T., Nakamori, K., Kinoshita, S., et al. (2023) · Cancer Science · doi:10.1111/cas.15976 · Cited by 19

Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis

Nishio, S., Murotani, K., Yamagami, W., Suzuki, S., Nakai, H., Kato, K., Tokunaga, H., Nomura, H., Yokoyama, Y., Takehara, K., et al. (2023) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.12.007 · Cited by 18

Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions

Wang, J., Zhao, F. Q., Zhang, Q., Sun, Z., Xiahou, Z., Wang, C., Liu, Y., & Yu, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1517679 · Cited by 18

‘Know thyself’ – host factors influencing cancer response to immune checkpoint inhibitors

Gunjur, A., Manrique-Rincón, A., Klein, O., Behren, A., Lawley, T. D., Welsh, S. J., & Adams, D. J. (2022) · The Journal of Pathology · doi:10.1002/path.5907 · Cited by 18

Risk factors for delayed neurocognitive recovery in elderly patients undergoing thoracic surgery

Wang, L., Chen, B., Liu, T., Luo, T., Kang, W., & Liu, W. (2023) · BMC Anesthesiology · doi:10.1186/s12871-023-02056-6 · Cited by 17

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma

Seretis, K. G., Sfaelos, K., Boptsi, E., Gaitanis, G., & Bassukas, I. D. (2024) · Cancers · doi:10.3390/cancers16051044 · Cited by 16

AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas

Ghosh, P., Campos, V. J., Vo, D. T., Guccione, C., Goheen-Holland, V., Tindle, C., Mazzini, G. S., He, Y., Alexandrov, L. B., Lippman, S. M., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.161334 · Cited by 16

Ratios of monocytes and neutrophils to lymphocytes in the blood predict benefit of CDK4/6 inhibitor treatment in metastatic breast cancer

Moukas, S. I., Kasimir‐Bauer, S., Tewes, M., Kolberg, H., Hoffmann, O., Kimmig, R., & Keup, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-47874-3 · Cited by 17

A combined nomogram based on radiomics and hematology to predict the pathological complete response of neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma

Yu, Y., Yi, Y., Wang, Z., Li, S., Zhang, B., Sang, Z., Zhang, L., Cao, Q., & Li, B. (2024) · BMC Cancer · doi:10.1186/s12885-024-12239-0 · Cited by 16

A combined model of serum neutrophil extracellular traps, CD 8 + T cells, and tumor proportion score provides better prediction of PD ‐1 inhibitor efficacy in patients with NSCLC

Guo, J., Shu, T., Zhang, H., Huang, N., Ren, J., Li, L., Wu, J., Wang, Y., Huang, Z., Bin, J., et al. (2024) · FEBS Journal · doi:10.1111/febs.17144 · Cited by 16

Aptameric Metal–Organic Framework Nanobiosensor

Dai, W., Wen, K., Meng, X., Yu, S., Zhao, J., & Lin, Q. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c03305 · Cited by 16

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

Loosen, S. H., Gorgulho, J., Jördens, M. S., Schulze-Hagen, M. F., Beier, F., Vucur, M., Schneider, A. T., Koppe, C., Mertens, A., Kather, J. N., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.646883 · Cited by 16

Prognostic value of inflammation‐immunity‐nutrition score in patients with hepatocellular carcinoma treated with anti‐PD‐1 therapy

Zhang, Z., Liang, Y., Zhong, D., Dai, Z., Shang, J., Lai, C., Zou, H., Yao, Y., Feng, T., & Huang, X. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24336 · Cited by 16

Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery

Plaja, A., Teruel, I., Ochoa-de-Olza, M., Cucurull, M., Arroyo, Á. J., Pardo, B., Ortiz, I., Gil-Martín, M., Piulats, J. M., Pla, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411420 · Cited by 15

Characteristics of aseptic meningitis-like attack—an underestimated phenotype of myelin oligodendrocyte glycoprotein antibody-associated disease

Gu, M., Mo, X., Fang, Z., Zhang, H., Lu, W., Shen, X., Yang, L., & Wang, W. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.104939 · Cited by 15

Associations of circulating immunomarkers with the efficacy of immunotherapy for primary hepatic carcinoma

Liu, S., Xu, W., Shu, H., Dai, Y., Du, Y., Liu, Y., Huang, L., & Sun, G. (2023) · Cancer Medicine · doi:10.1002/cam4.6754 · Cited by 14

Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers

Wang, J., Ma, X., Ma, Z., Ma, Y., Wang, J., & Cao, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.810539 · Cited by 14

Positive Correlation Between LTA Expression and Overall Immune Activity Suggests an Increased Probability of Survival in Uterine Corpus Endometrial Carcinoma

Shi, M., Luo, F., Shao, T., Zhang, H., Yang, T., Wei, Y., Chen, R., & Guo, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.793793 · Cited by 14

Utility of 18F-FDG uptake in predicting major pathological response to neoadjuvant immunotherapy in patients with resectable non‑small cell lung cancer

Chen, X., Bai, G., Zang, R., Song, P., Bie, F., Huai, Q., Li, Y., Liu, Y., Zhou, B., Bie, Y., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101725 · Cited by 13

Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics

Faria, S. S., Giannarelli, D., de Lima, V. C. C., Anwar, S. L., Casadei, C., Giorgi, U. D., Madonna, G., Ascierto, P. A., López, R. V. M., Chammas, R. J., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad303 · Cited by 15

Tumor mutational burden as a predictive biomarker for non-small cell lung cancer treated with immune checkpoint inhibitors of PD-1/PD-L1

Shao, M., Xu, Y.-P., Zhang, J., Mao, M., & Wang, M. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03370-8 · Cited by 14

The correlation between systemic inflammatory markers and efficiency for advanced gastric cancer patients treated with ICIs combined with chemotherapy

Dong, Q., Zhao, F., Li, Y., Song, F., Li, E., Gao, L., Xin, Y., Shen, G., Ren, D., Wang, M., et al. (2024) · Immunology · doi:10.1111/imm.13759 · Cited by 14

Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer

Issa, M., Tang, J., Guo, Y., Coss, C. C., Mace, T. A., Bischof, J. J., Phelps, M. A., Presley, C. J., & Owen, D. H. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2094772 · Cited by 14

Solving the puzzle of what makes immunotherapies work

Ma, X., & Chan, T. A.-T. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.011 · Cited by 15

Integrating Baseline Nutritional and Inflammatory Parameters with Post-Treatment EBV DNA Level to Predict Outcomes of Patients with De Novo Metastatic Nasopharyngeal Carcinoma Receiving Chemotherapy Combination PD-1 Inhibitor

Guo, J., Yang, Q., Jiang, Q., Gu, L.-W., Lin, H., & Guo, L. (2023) · Nutrients · doi:10.3390/nu15194262 · Cited by 13

The role of extracellular vesicle immune checkpoints in cancer

Zhang, W., Ou, M., Yang, P., & Ning, M. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae026 · Cited by 13

Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy

Butner, J. D., Dogra, P., Chung, C. D., Koay, E. J., Welsh, J. W., Hong, D. S., Vittorio Cristini, C., & Wang, Z. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00415-8 · Cited by 13

Predictive Value of Neutrophil‐to‐Lymphocyte Ratio for Immune Checkpoint Inhibitor‐Related Myocarditis Among Patients Treated for Non‐Small‐Cell Lung Cancer

Xue, J., Liu, C., Shao, J., Wang, L., Han, Y., Wang, J., & Wang, J. (2025) · Cancer Innovation · doi:10.1002/cai2.163 · Cited by 12

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma

You, H., Xu-Monette, Z. Y., Li, W., Nunns, H., Nagy, M. L., Bhagat, G., Fang, X., Zhu, F., Visco, C., Tzankov, A., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1928365 · Cited by 14

Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio

Tsai, J., Wei, S., Chen, C., Yang, S., Tseng, Y., Su, P., Lin, C., & Su, W. (2022) · Pharmaceuticals · doi:10.3390/ph15111407 · Cited by 12

Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea

Lee, J. Y., Kwon, J. H., Hur, J. Y., Yi, J. H., Lee, J., Cho, H., Do, Y. R., Jo, J., Kang, H. J., Koh, Y., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1042 · Cited by 12

APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research

Prelaj, A., Ganzinelli, M., Provenzano, L., Mazzeo, L., Viscardi, G., Metro, G., Galli, G., Agustoni, F., Corte, C. M. D., Spagnoletti, A., et al. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.12.012 · Cited by 12

Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases

Asano, Y., Hayashi, K., Takeuchi, A., Kato, S., Miwa, S., Taniguchi, Y., Okuda, M., Matsumoto, I., Yano, S., & Demura, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112276 · Cited by 12

NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma

Du, J., & Huang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-68048-9 · Cited by 12

Diagnostic value of combined prealbumin-to-fibrinogen and albumin-to-fibrinogen ratios in Hp-negative gastric cancer

Zhang, L., Qin, S., Lu, L., Huang, L., & Li, S. (2022) · The International Journal of Biological Markers · doi:10.1177/17246008211072875 · Cited by 12

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma

Tanaka, T., Takata, K., Yokoyama, K., Fukuda, H., Yamauchi, R., Fukunaga, A., Shakado, S., Sakisaka, S., & Hirai, F. (2022) · Current Oncology · doi:10.3390/curroncol29070381 · Cited by 12

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer

Meisel, A., de Wit, R., Oudard, S. M., Sartor, O. A., Stenner, F., Shun, Z., Foster, M. C., Ӧzatılgan, A., Eisenberger, M. A., & Bono, J. S. D. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221100022 · Cited by 14

Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study

Liu, S., Zhao, L., & Zhou, G. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1016085 · Cited by 12

Effects of CALM intervention on neutrophil-to-lymphocyte ratio (NLR), fear of cancer recurrence and quality of life in patients with lung cancer

Zhao, J., Wang, M., Huang, R., Xu, J., Chen, G., Yu, S., Tang, L., Yao, S., Li, W., & Cheng, H. (2023) · Supportive Care in Cancer · doi:10.1007/s00520-023-07929-7 · Cited by 12

The cell stress and immunity cycle in cancer: Toward next generation of cancer immunotherapy

Laureano, R. S., Vanmeerbeek, I., Sprooten, J., Govaerts, J., Naulaerts, S., & Garg, A. D. (2023) · Immunological Reviews · doi:10.1111/imr.13287 · Cited by 13

Machine Learning-assisted immunophenotyping of peripheral blood identifies innate immune cells as best predictor of response to induction chemo-immunotherapy in head and neck squamous cell carcinoma – knowledge obtained from the CheckRad-CD8 trial

Hecht, M., Frey, B., Gaipl, U. S., Tianyu, X., Eckstein, M., Donaubauer, A.-J., Klautke, G., Illmer, T., Fleischmann, M., Laban, S. A., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2023.100953 · Cited by 12

The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients

Li, L., Li, Y., Lu, M., Wang, Y., Li, Z., Hu, X., He, X., Gong, T., Luo, Y., Zhou, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1235158 · Cited by 12

The significance of preoperative neutrophil-to-lymphocyte ratio in predicting short-term complications and survival benefits of pancreaticoduodenectomy: A systematic review and meta-analysis

Wang, D., Wang, Y., Dong, X., Yu, M., & Cai, H. (2023) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2023.11.030 · Cited by 12

Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair

Park, Y.-G., Kim, H., Hyung, J., Park, Y. S., & Ryu, M. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01509-2 · Cited by 11

Tumor microenvironment RNA test to predict immunotherapy outcomes in advanced gastric cancer: The TIMES001 trial

Shi, M., Zeng, D., Luo, H., Xiao, J., Li, Y., Yuan, X., Huang, N., Wu, J., Zheng, S., Wu, J., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.006 · Cited by 12

Comparing neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil count (ANC) and derived NLR as predictive biomarkers in first-line immunotherapy for non-small cell lung cancer: a retrospective study

Longueville, E., Dewolf, M., Dalstein, V., Durlach, A., Vivien, A., Nawrocki‐Raby, B., Polette, M., Deslée, G., & Ancel, J. (2025) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-808 · Cited by 14

Beyond mismatch repair deficiency? Pre-treatment neutrophil-to-lymphocyte ratio is associated with improved overall survival in patients with recurrent endometrial cancer treated with immunotherapy

Barrington, D. A. M., Calo, C. A., Baek, J., Brown, M. D., Wagner, V. M., Gonzalez, L., Huffman, A., Benedict, J., & Bixel, K. L. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.07.010 · Cited by 11

Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study

Xiang, J., Gong, W., Sun, P. B., Wang, X., & Liu, A. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1229 · Cited by 11

Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study

Tanimura, K., Takeda, T., Yoshimura, A., Honda, R., Goda, S., Shiotsu, S., Fukui, M., Chihara, Y., Uryu, K., Takei, S., et al. (2023) · Cancers · doi:10.3390/cancers15174358 · Cited by 10

A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer

Baek, J. M., Cha, H., Moon, Y., Kim, L., Kwak, S. M., Park, E. S., & Nam, H.-S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051521 · Cited by 10

High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer

Dai, L., Tan, Q., Li, L., Lou, N., Zheng, C., Yang, J., Huang, L., Wang, S., Luo, R., Fan, G., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100749 · Cited by 10

Intestinal Microbiome Associated with Efficacy of Atezolizumab and Bevacizumab Therapy for Hepatocellular Carcinoma

Inukai, Y., Yamamoto, K., Honda, T., Yokoyama, S., Ito, T., Imai, N., Ishizu, Y., Nakamura, M., Ishigami, M., & Kawashima, H. (2024) · Cancers · doi:10.3390/cancers16091675 · Cited by 10

Immunotherapy in Colorectal Cancer — Finding the Achilles’ Heel

Park, R., & Saeed, A. (2024) · NEJM Evidence · doi:10.1056/evidra2300353 · Cited by 10

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio: Side by Side with Molecular Mutations in Patients with Non-Small Cell Lung Cancer—The INOLUNG Study

Budin, C. E., Cocuz, I. G., Enache, L. S., Rența, I. A., Cazacu, C., Pătrîntașu, D. E., Olteanu, M., Râjnoveanu, R., Ianoși, E. S., Râjnoveanu, A. G., et al. (2024) · Cancers · doi:10.3390/cancers16162903 · Cited by 12

Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer

Sugimoto, A., Kaneda, H., Yoshimoto, N., Nagata, K., Fujii, T., Michimoto, K., Ueno, S., Kamimori, T., Ishii, Y., Sakagami, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-70214-y · Cited by 10

Pretreatment neutrophil–lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumab

Kasahara, Y., Saijo, K., Ueta, R., Numakura, R., Sasaki, K., Yoshida, Y., Taniguchi, S. H., Ouchi, K., Komine, K., Imai, H., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-79130-7 · Cited by 10

Associations between neutrophil percentage-to-albumin ratio with all-cause and cause-specific mortality among US cancer survivors: evidence from NHANES 2005–2018

Wang, M., Wang, S., Hu, J., Wang, X., Pang, Y., & Sun, X. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1541609 · Cited by 10

Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors

Chen, X., Li, Z., Zhou, J., Wei, Q., Wang, X., & Jiang, R. (2022) · PeerJ · doi:10.7717/peerj.14566 · Cited by 10

Recent Developments in Blood Biomarkers in Neuro-oncology

Foster, J., Koptyra, M., & Bagley, S. J. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01321-y · Cited by 10

Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung Cancer

Shi, J., Li, J., Wang, H., Li, X., Wang, Q., Zhao, C., Cheng, L., Han, R., Chen, P., Guo, H., et al. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s430967 · Cited by 10

Recent advances in head and neck surgical oncology

Ritter, A., Levyn, H., & Shah, J. P. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27529 · Cited by 10

The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy

Numakura, K., Sekine, Y., Osawa, T., Naito, S., Tokairin, O., Muto, Y., Sobu, R., Kobayashi, M., Sasagawa, H., Yamamoto, R., et al. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02538-8 · Cited by 10

Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure

Park, J., Park, I., Kim, I.-H., Hur, J. Y., Hwang, I., Kim, C., Kim, H., Maeng, C. H., Park, K., Lee, M.-Y., et al. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100848 · Cited by 10

Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy

Li, Z., Duan, Y., Ke, Q., Wang, M., Cen, H., & Zhu, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1000460 · Cited by 9

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review

Mireștean, C. C., Stan, M. C., Schenker, M., Volovat, C. D., Volovăț, S. R., Iancu, D. T., Iancu, R. I., & Bădulescu, F. (2023) · Diagnostics · doi:10.3390/diagnostics13162620 · Cited by 9

Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis

Yu, H., Liu, Q., Wu, K., & Tang, S. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01408-x · Cited by 9

Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Brown, M. C., D’Anniballe, V. M., Boczkowski, D., Kandadi, H., Sheikh, N. A., Kornahrens, W., Heath, E. I., Thakur, A. B., Chen, W., Lum, L. G., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0439 · Cited by 9

Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer

Li, J., Tao, M., Liu, L., Liu, C., Ma, M., Liu, D., Zhang, P., Zhang, M., Xue, R., Gong, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03015-3 · Cited by 9

Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer

Mitchell, K. G., Lee, Y., Deboever, N., Negrao, M. V., Tran, H. T., Parra, E., Byers, L., Reuben, A., Federico, L., Bernatchez, C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011458 · Cited by 12

Response Prediction Model of Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Retrospective Study

Ueno, M., Kosaka, H., Iida, H., Ida, Y., Aoi, K., Mori, H., Miyamoto, A., Nishida, Y., Hayami, S., Kawai, M., et al. (2023) · Oncology · doi:10.1159/000531317 · Cited by 9

Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers

Ksienski, D., Truong, P. T., Bone, J. N., Egli, S., Clarkson, M., Patterson, T., Lesperance, M., & Lakkunarajah, S. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101789 · Cited by 10

Construction of a nomogram with IrAE and clinic character to predict the survival of advanced G/GEJ adenocarcinoma patients undergoing anti-PD-1 treatment

Wang, H., Chen, J.-H., Gao, W., Wu, Y., Wang, X., Lin, F.-Y., Chen, H., Wang, Y., Jiang, T., Pan, Z., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1432281 · Cited by 9

Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma

Kim, D. H., Jang, S. Y., & Keam, B. (2024) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2024.07.014 · Cited by 9

Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center

Kurzhals, J. K., Klee, G., Hagelstein, V., Zillikens, D., Terheyden, P. A. M., & Langan, E. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810723 · Cited by 9

Distant metastasis in head and neck squamous cell carcinoma variants: A population‐based study

Takenaka, Y., Uno, A., Tanaka, H., Takemoto, N., & Inohara, H. (2023) · Head & Neck · doi:10.1002/hed.27305 · Cited by 9

Development of 18F-Labeled Acridone Analogue for Tumor Imaging via Stimulator of Interferon Genes Targeting

Liu, H., Sun, Y., Li, J., Chen, Y., Liu, J., Fang, J., Yang, H., Feng, L., Peng, S., Zhuang, R., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00137 · Cited by 9

Clinical predictors of response to single‑agent immune checkpoint inhibitors in chemotherapy‑pretreated non‑small cell lung cancer

Musaelyan, A. A., Moiseyenko, F. V., Emileva, T., Oganesyan, A., Oganyan, K., Urtenova, M. A., Валентиновна, О. С., Chistyakov, I., Degtyarev, A., Akopov, A. L., et al. (2024) · Molecular and Clinical Oncology · doi:10.3892/mco.2024.2730 · Cited by 8

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a retrospective cohort study

Yan, H., Liu, J., Zhang, Y., Chen, S., Xu, J., Gao, D., Li, H., Fang, X., Wang, Y., Wang, H., et al. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-180 · Cited by 8

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma

Wang, Z., Zou, X., Wang, H., Hao, Z., Li, G., & Wang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1454720 · Cited by 9

Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy

Tintelnot, J., Paschold, L., Goekkurt, E., Schultheiß, C., Matschl, U., Cruz, M. S., Bauer, M., Wickenhauser, C., Thuss-Patience, P. C., Lorenzen, S., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0561 · Cited by 8

Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC

Chen, Y.-C., Chen, A., Hong, R., Huang, B. E., & Pirooznia, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-82903-9 · Cited by 9

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictor of Survival and Response to Therapy in Patients Treated with Immune Checkpoint InhibitorsPreprint

Valero, C., Lee, M. A., Hoen, D. R., Weiss, K. L., Kelly, D. J., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2020) · SSRN Electronic Journal · doi:10.2139/ssrn.3578798

High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).

Florou, V., Park, W., Torres, A. E., Algaze, S. D., Saravia, D., Wilky, B. A., Merchan, J. R., Hosein, P. J., Lockhart, A. C., & Junior, G. L. L. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e24109

Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis

Sacdalan, D. B., Lucero, J. A., & Sacdalan, D. L. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s153290 · Cited by 316

481P The predictive role of neutrophil-to-lymphocyte ratio in patients with solid cancers treated with immune checkpoint inhibitors: A pooled analysis of seven clinical trials of the German AIO study group

Dreikhausen, L., Wiest, I., Keller, R., Marin-Galiano, M., Darr, C., Stein, A., Binder, M., Tintelnot, J., Bozorgmehr, F., Pogorzelski, M., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.498

Pre-therapy neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio do not predict survival in patients treated with immune checkpoint inhibitors.

Mann, H., Mushtaq, M. U., Andrade-Gonzalez, X. A., Ahmed, A. T., & Gupta, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15092 · Cited by 1